ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Highly-sensitized"

  • 2017 American Transplant Congress

    Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.

    A. Vo, J. Choi, A. Peng, K. Lim, L. Varanasi, R. Najjar, E. Huang, D. Puliyanda, S. Jordan.

    Kidney Transplant, Cedars-Sinai Medical Center, LA, CA

    INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…
  • 2017 American Transplant Congress

    Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.

    A. Vo,1 S. Williamson,1 K. Myers,1 E. Huang,1 J. Choi,1 X. Zhang,2 A. Peng,1 R. Najjar,1 S. Jordan.1

    1Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; 2HLA Laboratory, Cedars-Sinai Medical Center, LA, CA

    Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…
  • 2017 American Transplant Congress

    Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization.

    S. Patel,1 J. Benken,1 S. Akkina,3 P. West-Thielke,2 J. Thielke,1 M. Campara,1 J. Oberholzer,2 E. Benedetti.2

    1Pharmacy, University of Illinois Hospital & Health Sciences System, Chicago; 2Surgery, University of Illinois Hospital & Health Sciences System, Chicago; 3Medicine, Loyola University Health System, Maywood

    Purpose: To determine outcomes of positive crossmatch (PXM) renal transplant recipients that failed to convert to a negative flow cytometry crossmatch (FCXM) despite desensitization. Methods:…
  • 2017 American Transplant Congress

    Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.

    S. Sethi, A. Vo, E. Huang, L. Varanasi, J. Choi, A. Peng, R. Najjar, S. Jordan.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

    IntroductionAcceptable patient and graft outcomes of ABO incompatible (ABOi) living donor kidney transplantation (LDKT) have been reported with the use of desensitization strategies. Data on…
  • 2017 American Transplant Congress

    Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.

    D. Okada,1 M. Okumi,1 K. Unagami,2 T. Shimizu,1 H. Ishida,1 K. Tanabe.1

    1Urology, Tokyo Women's Medical University, Tokyo, Japan; 2Nephrology, Tokyo Women's Medical University, Tokyo, Japan

    BackgroundLiving-donor kidney transplantation in cross-match (XM)-positive patients remains high-risk and requires an optimal desensitization protocol. We started a desensitization protocol for XM-positive patients in January…
  • 2017 American Transplant Congress

    Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.

    A. Babu,1,2,3 D. Briggs,3 D. Mitchell,1 N. Krishnan,2 R. Higgins,1 S. Daga.1,2,4

    1Warwick Medical School, University of Warwick, Coventry, United Kingdom; 2Nephrology and Transplantation, University Hospitals Coventrya and Warwickshire, Coventry, United Kingdom; 3Histocompatibility and Immunogenetics, NHS Blood and Transfusion, Birmingham, United Kingdom; 4Nephrology and Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Introduction. Complement activating donor specific antibodies may be associated with worse outcomes in a cohort of patients who have undergone HLA-AIT. We looked for differences…
  • 2017 American Transplant Congress

    Impact of Serum EDTA Treatment on Identification of Unacceptable Antigens for Kidney Transplant Candidates.

    J. Xin, N. Brown, R. Upchurch, J. Weidner, S. Marino.

    Pathology, University of Chicago Medicine, Chicago, IL

    BACKGROUND AND AIMS: The prozone effect is one factor causing false negative reactions in HLA antibody testing. EDTA, which is commonly used to remove this…
  • 2017 American Transplant Congress

    Effective Targeting Plasma Cells with Daratumumab (Anti-CD38) and Mozobil (Anti-CXCR4) in a Sensitized Non-Human Primate Model.

    J. Kwun,1 B. Ezekian,1 M. Manook,1 E. Branum,1 V. Curfman,1 J. Park,1,2 K. Freishlag,1 J. Yoon,1 S. Knechtle.1

    1Surgery, Duke Transplant Center, Durham, NC; 2Surgery, Samsung Medical Center, Seoul, Korea

    [Introduction] The presence of donor-specific antibodies (DSA) leads to antibody-mediated rejection (AMR) and decreased graft survival. Therefore efforts continue to be made to reduce DSA…
  • 2017 American Transplant Congress

    A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells.

    J. Driscoll,1 S. Tremblay,2 S. Knechtle,3 E. Woodle.2

    1Medicine, Univ Cincinnati, Cincinnati, OH; 2Surgery, Univ Cincinnati, Cincinnati, OH; 3Transplant, Duke Univ, Durham, NC

    Purpose: Historically, in vitro study of human plasma cells (PCs) has been greatly limited by their short survival (48-72 hrs). Therefore, systems that maintain viability…
  • 2016 American Transplant Congress

    Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).

    A. Nejad, A. Vo, J. Choi, S. Jordan.

    Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.

    INTRODUCTION: IVIG has become an essential tool in the treatment of sensitized patients prior to solid organ transplantation and is routinely used to treat viral…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences